MargotAnneChimaMDFAAD(She/Her)

Clinical Trials

• A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2) Start of enrollment: 2012 May 18

  Completed

  Phase 3

• A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV) Start of enrollment: 2015 May 26

  Completed

  Phase 3

• Secukinumab for Treatment of Atopic Dermatitis Start of enrollment: 2015 Nov 01

  Completed

  Phase 2

• Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Start of enrollment: 2015 Oct 15

  Active, not recruiting

  Phase 3

• A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata Start of enrollment: 2016 Jan 01

  Completed

  Phase 2

• LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris Start of enrollment: 2017 Feb 15

  Completed

  Phase 3

• A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis Start of enrollment: 2016 Oct 25

  Completed

  Phase 2

• Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata Start of enrollment: 2016 Dec 15

  Completed

  Phase 2

• Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis Start of enrollment: 2016 Dec 19

  Completed

  Phase 1

• The Efficacy and Safety of Secukinumab in Patients With Ichthyoses Start of enrollment: 2016 Dec 01

  Completed

  Phase 2

• A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS ) Start of enrollment: 2017 Feb 27

  Completed

  Phase 3

• Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis Start of enrollment: 2017 Feb 28

  Completed

  Phase 1

• Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis Start of enrollment: 2017 Mar 21

  Completed

  Phase 3

• A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus) Start of enrollment: 2017 Jul 18

  Terminated

  Phase 1, Phase 2

• A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo Start of enrollment: 2017 Jun 07

  Completed

  Phase 2

• Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo Start of enrollment: 2017 Apr 14

  Completed

  Phase 2

• Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata Start of enrollment: 2017 Aug 09

  Completed

  Phase 2

• A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis Start of enrollment: 2017 Apr 12

  Completed

  Phase 1

• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2) Start of enrollment: 2017 Jun 12

  Completed

  Phase 3

• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis Start of enrollment: 2017 Jul 03

  Completed

  Phase 2

• A Study of Long-term Baricitinib (LY3009104) Therapy in Atopic Dermatitis Start of enrollment: 2018 Mar 28

  Completed

  Phase 3

• Study to Investigate the Efficacy and Safety of Dupilumab Administered With Topical Corticosteroids (TCS) in Participants ≥6 to <12 Years With Severe Atopic Dermatitis (AD) Start of enrollment: 2017 Nov 17

  Completed

  Phase 3

• Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD) Start of enrollment: 2018 Jan 09

  Completed

  Phase 2

• Brodalumab in Subjects With Moderate to Severe Plaque Psoriasis Who Have Failed IL-17A Therapies Start of enrollment: 2017 Oct 31

  Completed

  Phase 4

• A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2018 Jan 30

  Completed

  Phase 2

• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants Start of enrollment: 2018 Jul 11

  Active, not recruiting

  Phase 3

• A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2) Start of enrollment: 2018 Jun 26

  Completed

  Phase 3

• A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Jun 27

  Terminated

  Phase 3

• Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema) Start of enrollment: 2018 Aug 13

  Active, not recruiting

  Phase 3

• The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis Start of enrollment: 2018 Sep 21

  Completed

  Phase 2

• Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Sep 29

  Terminated

  Phase 2

• Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis Start of enrollment: 2018 Oct 22

  Completed

  Phase 2

• PF-06651600 for the Treatment of Alopecia Areata Start of enrollment: 2018 Dec 03

  Completed

  Phase 2, Phase 3

• Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis Start of enrollment: 2018 Nov 12

  Terminated

  Phase 2

• Long-Term Safety of ARQ-151 Cream in Adult Subjects With Chronic Plaque Psoriasis Start of enrollment: 2018 Dec 18

  Completed

  Phase 2

• Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) Start of enrollment: 2019 Jun 11

  Active, not recruiting

• Join now to see all